If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The stock of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT ) is buoyant in trading today—up 30%, to a price of $26—its highest value since August 2022—after the company released its Q3 earnings .The group is for both ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The stock of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT ) is buoyant in trading today - up 30%, to a price of $26 - its highest value since August 2022 - after the company released itsThe group is for both novice ...

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidity shareholders. Halper Sadeh encourages Avidity shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Avidity and ...

公司概况与业务 - 公司为临床阶段生物技术公司 专注于利用CRISPR/Cas9技术开发遗传疾病治疗方法 [1] - 公司竞争对手包括CRISPR Therapeutics和Editas Medicine等其他生物技术公司 [1] 股价表现与市场数据 - 公司股票当前价格为13.97美元 当日下跌5.54% 日内交易区间为13.73美元至14.79美元 [4] - 公司股票过去52周最高价为28.25美元 最低价为5.90美元 [4] - 公司市值约为15亿美元 当日交易量为6,346,233股 [4] - JMP Securities为公司设定29美元的目标价 较当前14.79美元的价格存在96%的潜在上涨空间 [1][5] 临床试验进展与挑战 - MAGNITUDE临床试验项目针对Nex-Z疗法 因一起严重肝脏安全性事件导致方案暂停 [2] - 试验暂停内容包括暂停给药和患者筛查 是一项确保患者安全的预防性措施 [2][3] - 该试验旨在开发针对心脏病的一次性基因编辑疗法 [2] - 公司管理层已就此事件举行电话会议 并与专家及监管机构进行磋商 [3]

Royalty Pharma Plc (NASDAQ:RPRX) is one of the most profitable biotech stocks to buy. On October 10, Morgan Stanley analyst Terence Flynn slashed the price target on Royalty Pharma Plc (NASDAQ:RPRX) to $54 from $55 while keeping an overweight rating on the shares. Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? The rating update came ahead of Q3 earnings, with the firm telling investors in a preview for the biopharma group that it adjusted models for IQVIA trends along wi ...

Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) on October 21 with a $40 price target. Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? The analyst cited the promising clinical developments in the company’s portfolio, stating that the recent presentation at the ESMO meeting showed the efficacy of  rinatabart sesutecan (Rina-S)  for the treatment of endometrial ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21, setting a price target of $478. Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? The analyst based the optimistic rating on the positive potential of the company’s kidney franchise, stating that its innovativ ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on October 21 and set a price target of $90. BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds is Buying Similarly, Morgan Stanley analyst Sean Laaman also maintained a bullish stance on the stock on October 19, assigning it a Buy rating and a $104 price target. Laaman stated that BioMarin Pharma ...

长沙晚报掌上长沙10月28日讯（全媒体记者 刘军）28日，A股市场迎来4支生力军，禾元生物、西安奕 材、必贝特在科创板上市，泰凯英在北交所上市。引人注目的是，禾元生物、西安奕材、必贝特3家公 司在上市前并未盈利，成为科创板"1+6"改革以来成长层首批新注册公司。此3家公司成功上市，也标志 着未盈利的硬科技企业上市路径进一步畅通。 从4只新股上市首日表现来看都比较亮眼。泰凯英发行价为7.5元/股，开盘价为19.05元/股。截至收盘股 价为21.64元/股，涨幅180.27%。禾元生物发行价为29.06元/股，开盘价为88.00元/股。截至收盘股价为 91.10元/股，涨幅为178.91%。西安奕材发行价为8.62元/股，开盘价为39.78元/股，截至收盘股价为25.75 元/股，涨幅为211.40%。必贝特发行价为17.78元/股，开盘价为48.90/股。截至收盘股价为31.01元/股， 涨幅为82.96%。 今年6月18日，证监会宣布科创板"1+6"政策，设立科创成长层，重点服务技术有较大突破、商业前景广 阔、持续研发投入大，但目前仍处于未盈利阶段的科技型企业。旨在有针对性地改革优化科创板发行上 市等制度，着 ...

ETHZilla Corporation (NASDAQ: ETHZ ), the former clinical-stage biotech company that faced cash constraints and poor liquidity and had to slow down R&D activities significantly, has become one of the fastest-growing Ethereum USD (Mandela has been a cryptocurrency enthusiast and trader since 2017. He loves coding and writing about cryptocurrencies and crypto investment strategies. He has an in-depth understanding of distributed ledger technology, the Web3 technology stack, and crypto investing. He enjoys res ...